PeptiDream : Corporate Presentation（November 2023, English version)(2MB)

Corporate Presentation

November 2023

PeptiDream Inc.

(TSE : 4587)

PeptiDream - Investment Highlights

Global Leader in the Discovery and Development of Macrocyclic Peptide Therapeutics

Industry Leading

Peptide Discovery

Platform

PeptiDream's proprietary Peptide Discovery Platform System (PDPS) technology

• Unparalleled peptide library generation (trillions) and hit finding platform
• Unrivaled # of building blocks
• Continuous evolution of the technology, translating learnings from advancing programs back into the platform improvements
• World-classchemistry, biology, bioinformatics, structural biology, modeling, profiling and ADME teams to turn hit peptide candidates into development candidates

Strong IP portfolio

Foundational in

Leading and Expanding

the Field

PeptiDream at the center of a large and diverse network of discovery and development partnerships

• Collaborations with large, mid, and small sized pharma companies all over the world creating the ecosystem
• Licensing of the PDPS discovery platform to global and Japan pharma partners solidifies the network around a common platform.
• Further grow the network and modality through strategic partnerships
• Develop products in house and license to network partners

Diverse Big Pharma-

Sized Pipeline

PeptiDream has a large diverse pipeline of programs spanning peptide modality, disease areas and development partners

• Over 120+ discovery and development programs
• Spans variety of peptide modalities, from peptide therapeutics to peptide-drug conjugates (PDCs) to multi- functional peptide conjugates (MPCs)
• Across broad range of therapeutic areas and discovery and development partners

Markets 24 radiodiagnostic and 8 radiotherapeutic products in Japan through PDRadiopharma

Business Model

Driving Profitability

and Growth

PeptiDream's unique multifaceted business model has allowed company to be profitable since 2011

• Year over year growth in revenue and profits from three complementary and synergistic business strategies
• Grow the business and the pipeline through partnerships and cash flow, not through capital raises
• Phenomenal growth potential as the pipeline matures

Japan radiopharmaceutical and radiodiagnostic business provides stable, positive cash flow

2

Listed on the TSE Mothers

2013

(Ticker: 4587)

PeptiDream - Historical Snapshot

From University Startup to Growing Japan-Based Drug Discovery Powerhouse

PeptiDream Inc.

Selected as a constituent of The JPX Prime 150 Index

2023

PDRadiopharma Inc.

PDRadiopharma Chiba Plant	Acquired PDRadiopharma Inc.
	(Radiopharmaceutical business)
	Changed to the Prime Market
	of the TSE

Relocated corporate headquarters

2022

JPY 30.0 B1)/

704 employees2)

JPY 26.8 B/

PeptiDream headquarters (Kawasaki)

to Kawasaki

680 employees

PeptiDream Founded

(Spinout from the University of Tokyo)

2006

Revenue/

Total employees

Changed to the first section of the TSE

	2015
	JPY 2.4B /
JPY 0.6B /	50 employees
32 employees

2017

JPY 4.8B/

68 employees

Note: Financial numbers prior to FY2021 are based on JGAAP, IFRS is applied after FY2022.

1) Consolidated revenue forecast for FY2023 2) PeptiDream Inc.: 208 employees, PDRadiopharma Inc.: 496 employees (as of June 2023)

3

PeptiDream's Equity Holdings

Key progress on programs with the partners

Computational Drug Discovery (2017-)

• Partnering discussions in progress for KIT inhibitor program

Radiopharmaceutical

Development,

Manufacturing and

Sales (2022-)

• Indication expansion of AMYViD approved for the use of MCI
• In-licensingdiscussions to accelerate short-term pipeline growth

Note: (Year) represents the year that PeptiDream invested in the company.

<5%

2%

<15%

39.5%

39.4%

100%

Strategic Partner in Radiopharmaceuticals (2020-)

• Announced the 2nd development candidate from PeptiDream collaboration
• IND-enablingstudies and imaging studies in humans on-going, with the plan to file INDs in H1 2024

Peptide CDMO Business (2017-)

• Expanding the peptide and oligonucleotide API manufacturing business
• Progress in development of new platform technologies

Growth Factor Business (2020-)

• 7 products currently in the market
• Targeting market opportunities in lab-grown meat in addition to regenerative medicine and cell therapy
• Partnering discussions for therapeutic use

COVID-19 Therapeutics (2020-)

• Confirmed favorable safety profile in humans (clinical research in Japan)
• Anticipate US phase 1 trial to start in Q1 2024, with financial support from AMED

4

Macrocyclic Peptides as an Expanding Drug Class

Several Approved Macrocyclic Peptide Drugs With Over $1B in Annual Sales

Long History of Macrocyclic Peptides As Drugs Macrocyclic Peptides Have Positive Features of Both Small & Large Molecules

Molecular weight

									Large
Small
0.6kD	2.5kD				150kD~
Small molecules		Macrocyclic peptides		Large molecules

•	Good at recognizing	• High affinity and specificity	•	High affinity and
	binding pockets but	•	Good at inhibiting PPIs		specificity
	not PPIs or shallow	• Good at recognizing shallow	•	Good at inhibiting PPIs
	surfaces		interacting surfaces and	•	Good at recognizing
•	Orally bioavailable		binding pockets		shallow interacting
•	Membrane permeable	•	Oral bioavailability possible		surfaces of proteins
•	Near limitless targets	•	Near limitless targets	• Not oral - limited targets
•	However difficult and	• Relative ease and speed in	• Relative ease and speed
	time consuming to find		finding a suitable hit		in finding a suitable hit

Most approved macrocyclic drugs arose from natural products, limiting discovery!

Note: 1) Approved by CDER (Center for Drug Evaluation and Research) as new molecular entities.	5
Source: FDA, Chemistry & Engineering News, Company websites.

PDPS is a Powerful Peptide Discovery Platform

Unparalleled Macrocyclic Peptide Library Generation and Hit Finding Technology

Amino Acid (AA) Building Blocks

PeptiDream's 3000+ AAs:

•	Canonical AAs
•	Non-canonical AAs
	‒ L-AAs w/ novel side chains
	‒	N-alkyl AAs
	‒	D-AAs

Randomized DNA library

10 positions with 20

building blocks

2010 =

10,240,000,000,000 different peptides in a library

Trillions of peptides

in each library

Cyclic peptide

Coding sequence

• Robust, cell-free synthesis derived by nature's way of making peptides
• Each peptide "barcoded" via its mRNA/cDNA tag

‒	β-AAs
‒	Peptoid AAs

etc.

Continuously evolving

platform

• Continuous expansion of AA building blocks that libraries can be made with and optimized from ( grew from 200 to >3,000 )
• Automation of the platform (high throughput)
• Growing in-silico methods, computer simulation and modeling to predict optimal features
• Protected by a broad patent portfolio

Amplify recovered

sequences and repeat

Amplify candidate peptides over iterative rounds of selection

Target protein

Magnetic bead

Automated PDPS

Workstation

Peptide binder

High rate of hit finding success

• Discover high affinity and highly selective macrocyclic peptide binders to almost any target quickly and efficiently
  Yields unique hit candidates unlike any other technology
  Technology can be used to optimize and fine-tune the drug-like properties

6

The Expanding Applications of Macrocyclic Peptides

Turning PDPS Identified Seeds Into a Growing Array of Peptide Therapeutics

PDPS Identified

Macrocyclic

Peptide Seeds

Peptide Drugs

Small Molecule Drugs

Peptide-RI

PDCs Peptide-Oligo

Peptide-Cytotoxic

Bifunctional

MPCs

Trifunctional

Key Advantages

• Affinity and selectivity comparable to antibodies
• Unique epitopes and MOAs
• Differentiating PK & ADME characteristics
• Oral administration & other routes possible
• Enable small molecule discovery
• Peptide ideal at targeting and payload delivery
• More amenable to a greater array of payloads compared to other modalities.
• Simple robust conjugation chemistry
• Tunable PK/ Differentiating route of elimination
• RI-PDC: Ideal fit with radioisotope payloads
• Oligo-PDC: Enable delivery of oligonucleotide/siRNA drugs to specific tissues/cells
• Cytotoxic-PDC: unique beneficial attributes
• Extremely powerful and modular
• Design and generate multi-functional peptide drugs by conjugating/linking several peptides with different MOAs together
• Various configurations, such as bifunctional, trifunctional, and more

7

Expansion of R&D Capabilities

Unlocking Greater Value and Increasing Control

PeptiDream's role in collaborations has increased over time

R&D Capabilities (2010)

Hit ID	Lead	Lead	Preclinical	Phase 1
Generation	Optimization	Studies

R&D Capabilities (2023)

Hit ID	Lead	Lead	Preclinical	Phase 1
Generation	Optimization	Studies

Increasing research capabilities allows for:

• Greater role in partnerships
• More control over program progress
• Larger deal financials
• Ability to take internal programs further before partnering/ out-licensing

					Radiopharmaceutical Operations
# of				(Sales, Commercial, Distribution,
Increasing value of
			Manufacturing, R&D)
employees	all programs
800
			PDPS automation 680
				Translational Research
600
		ADME/PK		PDRadiopharma
			Structural Biology
400
	Discovery Biology
		Medicinal Chemistry
		Modeling/Informatics
200		Peptide Chemistry
		Amino Acid Expansion

PDPS	PeptiDream

0

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Company		Relocation to		Acquisition of
founded		Kawasaki		PDRadiopharma

8

Unique Multifaceted Business Model

Business Model Spread Across 4 Strategies

Drug Discovery and Development Business Segment

1	Collaboration Drug
Discovery and Development

2 PDPS Technology Licensing

Strategic Alliance/

3 In-House Program

Radiopharmaceuticals Business Segment

100%

Revenue Source

Short-termMid-termLong-term

Upfront

Development

Research fundingRoyalties milestones

Preclinical milestones

Licensing and	Development	Royalties
maintenance fees	milestones

Out-licensing fee,

developmentRoyalties milestones

R&D, Manufacturing and Sales of

4 Radiopharmaceuticals/Diagnostics

Product Sales	Product Sales	Product Sales
(Existing	(In-licensed	(PeptiDream
products)	products)	products)

9

1 Collaboration Drug Discovery and Development

Combining PeptiDream's Expertise With Big Pharma's Drug Development Know-How and Capabilities

• Lead & Expand: Leadership position in the space - drive expansion of macrocyclic peptide ecosystem
• More Programs: Allows PeptiDream to work on a larger number of programs with less staff/resources than otherwise possible
• Build Expertise: Continuously build in-house expertise by working with and learning from big pharma
• Diversify Risk: Diversify business risk with a broad portfolio of programs and partners (success not tied to any one program or partner)

5-Year Snapshot
2018	2019	2020	2021	2022	2023

Peptide Therapeutics

Multiple undisclosed targets

PDC		PDC		PDC
PDCs for brain/CNS		Radiological diagnostics and
delivery		novel applications		PDCs for CNS diseases

Peptide Therapeutics Peptide Therapeutics

cMET agonist program

Multiple undisclosed targets

Peptide Therapeutics		PDC

Ophthalmic disease targets

PDCs with RI payloads

Peptide Therapeutics		PDC		PDC		PDC
		Peptide-siRNA delivery to		PDCs with cytotoxic
COVID-19 therapies		extrahepatic tissues		payloads		Targeted protein degraders

Note: Merck & Co., Inc., Rahway, NJ, USA.

PDC		PDC		PDC
PDCs for neuromuscular		PDCs targeting specific cells
diseases		and tissues		Peptide-RI drug conjugates

10